Study of ABT-263 When Administered in Combination With Either Fludarabine/Cyclophosphamide/Rituximab or Bendamustine/Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
about
Study of ABT-263 When Administered in Combination With Either Fludarabine/Cyclophosphamide/Rituximab or Bendamustine/Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
description
clinical trial
@en
klinisch onderzoek
@nl
name
Study of ABT-263 When Administ ...... y Chronic Lymphocytic Leukemia
@en
type
label
Study of ABT-263 When Administ ...... y Chronic Lymphocytic Leukemia
@en
prefLabel
Study of ABT-263 When Administ ...... y Chronic Lymphocytic Leukemia
@en
P4844
P1050
P1476
A Phase 1 Study Evaluating the ...... y Chronic Lymphocytic Leukemia
@en
P3098
NCT00868413
P580
2009-11-01T00:00:00Z
P582
2013-05-01T00:00:00Z